Previous 10 | Next 10 |
Sangamo Therapeutics ( SGMO -1% ) is down again, albeit modestly on average volume. Shares have sold off over 30% since touching $12.33 on Monday. More news on: Sangamo Therapeutics, Inc., bluebird bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
The following slide deck was published by bluebird bio, Inc. in conjunction with this Read more ...
Shares of bluebird bio (NASDAQ: BLUE) jumped 11.9% today after the biotech presented data from a pair of clinical trials at the American Society of Hematology (ASH) annual meeting. Bluebird presented data from the late-stage Northstar-3 clinical trial, showing that its LentiGlobin gene ther...
Investing in biotech stocks isn't for the faint of heart. These companies often boast one (or more) potential blockbuster drugs, but a single misstep on the path to approval -- such as a negative clinical trial result or a regulatory setback -- can send their share prices crashing. Still, if y...
Bluebird bio ( BLUE +3% ) and collaboration partner Bristol-Myers Squibb ( BMY +0.5% ) (via its acquisition of Celgene) announce updated results from a two-part open-label Phase 1 clinical trial, CRB-402 , evaluating BCMA-targeted CAR T candidate bb21217 in heavily pretreated patients...
Safety profile consistent with known toxicities of CAR T therapies CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18 bluebird bio, Inc. (Nasdaq: BLUE) and Bristol-Myers Squibb (NYSE: BMY) announced updated safety and ef...
More than four years of durable transfusion independence (TI), stable total hemoglobin (Hb) levels and reduced liver iron concentrations in completed Phase 1/2 Northstar (HGB-204) study in patients who do not have a β 0 / β 0 genotype Ninety percent of evaluable pat...
Allakos ( ALLK ) was up a whopping 40% in a day's trading on 8x surge in volume on Friday on what has been called "sales chatter." I covered ALLK in August in a mostly bearish article after it almost tripled overnight after results from a Phase 2 study of lead candidate AK002 was publis...
Synthorx (NASDAQ: THOR ) +169% on being acquired by Sanofi. More news on: Synthorx, Inc., XBiotech Inc., ArQule, Inc., Stocks on the move, Read more ...
New data from an ongoing open-label Phase 1/2 clinical trial, HGB-206 , evaluating bluebird bio's (NASDAQ: BLUE ) LentiGlobin gene therapy in sickle cell disease (SCD) patients showed a significant treatment benefit. The results were presented at ASH in Orlando. More news on: bluebird ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...